Genetic Polymorphisms and the Impact of a Higher Clopidogrel Dose Regimen on Active Metabolite Exposure and Antiplatelet Response in Healthy Subjects
about
The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?Pharmacogenomics and cardiovascular diseasePharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?Identification of alcohol-dependent clopidogrel metabolites using conventional liquid chromatography/triple quadrupole mass spectrometryEffectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers.ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysisFormation of the thiol conjugates and active metabolite of clopidogrel by human liver microsomes.Haplotype of platelet receptor P2RY12 gene is associated with residual clopidogrel on-treatment platelet reactivityGenetic determinants of response to cardiovascular drugs.Clinical impact of genetically determined platelet reactivity.Pharmacogenomics of anti-platelet and anti-coagulation therapy.Clinical pharmacokinetics and pharmacodynamics of clopidogrel.Role of Genetic Testing in Patients undergoing Percutaneous Coronary Intervention.Optimizing clopidogrel dose response: a new clinical algorithm comprising CYP2C19 pharmacogenetics and drug interactions"Influence of methadone on clopidogrel in addicts on methadone maintenance therapy" Drug interaction between methadone and clopidogrel.Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1.Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine.The effect of induction of CYP3A4 by St John's wort on ambrisentan plasma pharmacokinetics in volunteers of known CYP2C19 genotype.Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response.A synergic effect between CYP2C19*2, CYP2C19*3 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients.Clopidogrel, CYP2C19 and proton pump inhibitors: what we know and what it means.
P2860
Q26801867-D2A4E032-5AC2-491F-9939-2758AF6CAA02Q26823542-DAAB8F2A-A9B2-4122-AAA2-E7DB2B7971B4Q26997380-331DC273-ECD5-41ED-9CE0-01F6012C213BQ27022443-E4D34410-3BB3-4E0C-A91B-E7E934B1CD32Q33666595-6388CC6D-1AAA-4FF2-A815-4019BD933DEBQ33963651-3E560484-F00C-4F26-8004-5A73336AEF51Q34441355-CE65386E-E851-4816-A1F6-A00149285125Q36105504-122BF848-05C0-4208-B0AA-2691DC2CBD9DQ37602843-F53ED206-D7D3-4BB8-B6D4-9628F3CC0C9AQ37989811-1006A479-8227-4F4C-8CA4-FFC5BC4EC696Q38059616-BA712695-C434-4340-9F14-4B87FCA4957AQ38116753-32A73A4F-87B2-4FAC-9437-4209A36DB9A0Q38307535-47875768-B95C-491B-9E9F-08CF6FF26982Q38401281-984977C8-A8F7-46C4-9630-6B395D9FC900Q41504194-5602EB1A-4A2D-46C9-9CA8-7072628E540CQ41936905-ABA2798C-0924-44C7-AFA3-F1C4D7E9267EQ42710782-8F0B9A61-9F92-4510-A73F-FA6FD853E92EQ47554139-A7404DDB-717B-467A-8C04-E80692C96197Q47803945-C7E45160-A12E-4396-86F4-DFDFAC6E01ABQ48183000-A35E5377-6C02-46ED-939D-D798651789A3Q48217024-E8F9CC57-FABF-4AFB-9DE9-65BDF000B4F6Q50050774-7A047B44-E000-46EA-AC45-E4B7F46E8614
P2860
Genetic Polymorphisms and the Impact of a Higher Clopidogrel Dose Regimen on Active Metabolite Exposure and Antiplatelet Response in Healthy Subjects
description
article
@en
im Juni 2011 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в червні 2011
@uk
name
Genetic Polymorphisms and the ...... t Response in Healthy Subjects
@en
Genetic Polymorphisms and the ...... t Response in Healthy Subjects
@nl
type
label
Genetic Polymorphisms and the ...... t Response in Healthy Subjects
@en
Genetic Polymorphisms and the ...... t Response in Healthy Subjects
@nl
prefLabel
Genetic Polymorphisms and the ...... t Response in Healthy Subjects
@en
Genetic Polymorphisms and the ...... t Response in Healthy Subjects
@nl
P2093
P2860
P356
P1476
Genetic polymorphisms and the ...... t response in healthy subjects
@en
P2093
L Bergougnan
P2860
P304
P356
10.1038/CLPT.2011.127
P407
P577
2011-06-29T00:00:00Z